Previous 10 | Next 10 |
2024-01-18 16:41:08 ET More on Qiagen Qiagen N.V. (QGEN) Q3 2023 Earnings Call Transcript Qiagen quickly ticks higher amid takeover speculation FDA OKs Qiagen's NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems Seeking Alpha’s Qu...
Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholder...
2024-01-16 10:58:26 ET Qiagen N.V. (QGEN) Q3 2023 Earnings Call Transcript FDA OKs Qiagen's NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems QIAGEN expands business in Middle East with new regional headquarters Seeking Alpha’s Quant...
Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 Londo...
Germantown, Maryland, and Venlo, the Netherlands, Jan. 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical...
Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayme...
Venlo, the Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These investments will support QDI, the b...
2024-01-03 03:00:26 ET More on Qiagen Seeking Alpha’s Quant Rating on Qiagen Historical earnings data for Qiagen Financial information for Qiagen For further details see: QIAGEN expands business in Middle East with new regional headquarters
Venlo, the Netherlands, Muscat, Oman, and Riyadh, Saudi Arabia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant expansion of its business in the Middle East region, which includes three major developments: In early 2024, QIA...
2023-12-23 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Qiagen N.V. Company Name:
QGEN Stock Symbol:
NYSE Market:
Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of hereditary and somatic diseases, has received ...
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat...
Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity d...